N
CSTL icon

Nuveen’s Castle Biosciences CSTL Stock Holding History

Nuveen’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8M Sell
522,127
-2,554
-0.5% -$83.7K ﹤0.01% 1411
2025
Q4 		$20.4M Sell
524,681
-432,400
-45% -$13.9M 0.01% 1135
2025
Q3 		$21.8M Sell
957,081
-116,026
-11% -$2.36M 0.01% 1098
2025
Q2 		$21.9M Buy
1,073,107
+401,296
+60% +$7.43M 0.01% 1039
2025
Q1 		$11.9M Buy
671,811
+206,285
+44% +$5.11M ﹤0.01% 1447
2024
Q4 		$12.4M Sell
465,526
-77,067
-14% -$2.35M ﹤0.01% 1483
2024
Q3 		$15.5M Buy
542,593
+256,082
+89% +$6.52M ﹤0.01% 1349
2024
Q2 		$6.24M Buy
286,511
+96,883
+51% +$2.16M ﹤0.01% 1839
2024
Q1 		$4.2M Buy
189,628
+7,154
+4% +$156K ﹤0.01% 2078
2023
Q4 		$3.94M Buy
182,474
+6,190
+4% +$109K ﹤0.01% 2095
2023
Q3 		$2.98M Sell
176,284
-240,130
-58% -$4.2M ﹤0.01% 2127
2023
Q2 		$5.71M Buy
416,414
+10,656
+3% +$216K ﹤0.01% 1840
2023
Q1 		$9.22M Buy
405,758
+103,109
+34% +$2.52M ﹤0.01% 1535
2022
Q4 		$7.12M Buy
302,649
+191,974
+173% +$4.45M ﹤0.01% 1709
2022
Q3 		$2.89M Sell
110,675
-1,980
-2% -$55.5K ﹤0.01% 2196
2022
Q2 		$2.47M Buy
112,655
+40,888
+57% +$950K ﹤0.01% 2330
2022
Q1 		$3.13M Buy
71,767
+776
+1% +$32.1K ﹤0.01% 2294
2021
Q4 		$2.76M Sell
70,991
-5,521
-7% -$288K ﹤0.01% 2405
2021
Q3 		$5.92M Sell
76,512
-5,474
-7% -$385K ﹤0.01% 2115
2021
Q2 		$6.01M Buy
81,986
+30,342
+59% +$2M ﹤0.01% 2150
2021
Q1 		$3.54M Sell
51,644
-29,149
-36% -$2.19M ﹤0.01% 2339
2020
Q4 		$5.42M Sell
80,793
-3,509
-4% -$190K ﹤0.01% 2030
2020
Q3 		$4.34M Buy
84,302
+29,462
+54% +$1.31M ﹤0.01% 1990
2020
Q2 		$2.07M Sell
54,840
-9,625
-15% -$329K ﹤0.01% 2328
2020
Q1 		$1.92M Sell
64,465
-50,272
-44% -$1.52M ﹤0.01% 2211
2019
Q4 		$3.94M Sell
114,737
-50,569
-31% -$1.24M ﹤0.01% 2114
2019
Q3 		$2.99M Buy
+165,306
New +$3.66M ﹤0.01% 2213

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen's CSTL Position: Q1 2026 in Review

Nuveen reduced its Castle Biosciences (CSTL) stake by 0.49% in Q1 2026, selling an estimated $83.7K and leaving 522,127 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

Nuveen first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $21.9M in Q2 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Nuveen held 522,127 shares of Castle Biosciences worth $12.8M as of Q1 2026.
  • Nuveen sold 2,554 Castle Biosciences shares in Q1 2026, an estimated $83.7K.
  • Castle Biosciences made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1411 holding.
  • Nuveen first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • Nuveen's Castle Biosciences position peaked at $21.9M in Q2 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.